Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Jun;29 Suppl 1(0 1):S91-8.
doi: 10.1097/QAD.0000000000000665.

Disclosure of their HIV status to perinatally infected youth using the adapted Blasini disclosure model in Haiti and the Dominican Republic: preliminary results

Consuelo M Beck-Sagué  1 , Jessy Dévieux, Maria Claudia Pinzón-Iregui, Leonel Lerebours-Nadal, Rosa Abreu-Pérez, Rachel Bertrand, Vanessa Rouzier, Stephanie Gaston, Gladys Ibanez, Mina Halpern, Jean W Pape, Patricia Dorceus, Sharice M Preston, Andrew G Dean, Stephen W Nicholas, Ileana Blasini
Affiliations
Comparative Study

Disclosure of their HIV status to perinatally infected youth using the adapted Blasini disclosure model in Haiti and the Dominican Republic: preliminary results

Consuelo M Beck-Sagué et al. AIDS. 2015 Jun.

Abstract

Objectives: To assess the safety, acceptability, and preliminary efficacy of a culturally-adapted disclosure intervention for perinatally HIV-infected combined antiretroviral therapy patients in Haiti and the Dominican Republic.

Design: A quasi-experimental trial was conducted comparing caregiver-youth pairs who completed the intervention [adapted Blasini disclosure model (aBDM)] to pairs who discontinued aBDM participation before disclosure. aBDM consists of five components: structured healthcare worker training; one-on one pre-disclosure intervention/education sessions for youth (describing pediatric chronic diseases including cancer, diabetes and HIV) and for caregivers (strengthening capacity for disclosure); a scheduled supportive disclosure session; and one-on-one postdisclosure support for caregivers and youth.

Methods: Caregivers of nondisclosed combined antiretroviral therapy patients aged 10.0-17.8 years were invited to participate. Data were collected by separate one-on-one face-to-face interviews of caregivers and youth by study staff and medical record review by pediatricians at enrollment and 3 months after disclosure or after intervention discontinuation.

Results: To date, 65 Dominican Republic and 27 Haiti caregiver-youth pairs have enrolled. At enrollment, only 46.4% of youth had viral suppression and 43.4% of caregivers had clinically significant depressive symptomatology. To date, two serious study-related adverse events have occurred. Seven of the 92 (7.6%, 6 in the Dominican Republic) enrolled pairs discontinued participation before disclosure and 39 had completed postdisclosure participation. Median plasma HIV-RNA concentration was lower in youth who completed aBDM than in youth who discontinued participation before aBDM disclosure (<40 versus 8673 copies/ml; P = 0.027). Completers expressed considerable satisfaction with aBDM.

Conclusion: Preliminary results suggest safety, acceptability, and possible effectiveness of the aBDM.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. Adapted Blasini Disclosure model procedures and Tasker Theory of Disclosure
Adapted from Blasini et al. [19] and Tasker [29].
See this image and copyright information in PMC

References

    1. Joint United Nations Programme on HIV AIDS (UNAIDS) Global report: UNAIDS report on the global AIDS epidemic. 2013 http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiolo.... [Accessed 1 November 2014]
    1. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR, 3rd, et al. Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522–1528. - PubMed
    1. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008;8:477–489. - PubMed
    1. George E, Noël F, Bois G, Cassagnol R, Estavien L, Rouzier P, et al. Antiretroviral therapy for HIV-1-infected children in Haiti. J Infect Dis. 2007;195:1411–1418. - PubMed
    1. Leonardo J, Torres M, Lerebours Nadal L, Geyer M, Sparrow C, De La Rosa M, et al. AIDS 2008-XVII International AIDS Conference. Mexico City, Mexico: Death at an early age: highly-active antiretroviral therapy (HAART) and mortality in pediatric patients living with HIV/AIDS (PPLWHA), La Romana, Dominican Republic (DR) Abstract no.THPE0716, August 3-8, 2008.

Publication types

Substances